αB-Crystallin is a novel oncoprotein that predicts poor clinical outcome in breast cancer
J. Clin. Invest. Jose V. Moyano, et al. 116:261 doi:10.1172/JCI25888 [Go to this article.]

Figure 3
The neoplastic abnormalities in mammary acini overexpressing αB-crystallin are MEK dependent. (A) Immunoblot analysis of MCF-10A cells or MCF-10A pools grown as monolayers in low serum without added EGF. p-, phosphorylated. (B) MCF-10A pools were plated on Matrigel in the presence of vehicle, 10 μM SB 203580 (SB), 10 μM PD 98059 (PD), 1 μM U 0126 (U), 10 μM LY 294002 (LY), or 0.1 μM wortmannin (Wort). Representative phase contrast images of day-12 acini. (C) Representative confocal images of day-12 αB-WT acini cultured from day 0 in the presence of vehicle, SB 203580, or PD 98059 (mid-acini cross sections). Acini were immunostained with antibodies to GM130 (red; αB-crystallin, green), laminin-5 (red; αB-crystallin, green), integrin β4 (red; αB-crystallin, green) or Ki-67 (green; αB-crystallin, red). Nuclei were stained with DAPI (blue). (D) Percentage of day-12 acini with abnormal morphology (enlarged structures with filled lumens). MCF-10A pools were treated as in B. Data are mean ± SD (n = 3; at least 100 acini scored per experiment). ***P < 0.001 versus control. Scale bars: 100 μm (B); 50 μm (C).